Difficulty: Medium
Average Score: 78%
Practice
Which of the following is FALSE concerning selective COX 2 inhibitors?:
Correct answer
B
Rationale
Selective COX-2 inhibitors are a class of drugs that selectively inhibit the cyclooxygenase-2 enzyme, which is involved in inflammation and pain. The correct answer, option B, stating that selective COX-2 inhibitors have a low risk of cardiotoxicity and stroke, is false. In fact, these drugs have been associated with an increased risk of cardiovascular events, such as heart attacks and strokes. This risk led to the withdrawal of some COX-2 inhibitors from the market.
Option A, stating that selective COX-2 inhibitors are associated with a low risk of gastric ulceration, is true. Compared to non-selective NSAIDs, COX-2 inhibitors are less likely to cause gastric ulcers and gastrointestinal bleeding.
Option C, claiming that nephrotoxicity is a serious adverse effect of selective COX-2 inhibitors, is incorrect. Nephrotoxicity is not a common side effect associated with these drugs. However, renal function should be monitored in patients taking COX-2 inhibitors as a precaution.
Option D states that Celecoxib should not be given to patients with sulfonamide allergy. This statement is true because Celecoxib has a sulfonamide moiety in its structure, which may cross-react with sulfonamide antibiotics and trigger an allergic reaction in susceptible individuals.
In an educational context, understanding the pharmacological properties and potential adverse effects of selective COX-2 inhibitors is crucial for healthcare professionals in making informed decisions about their use in clinical practice. It is essential to weigh the benefits of these drugs in managing pain and inflammation against their potential risks, such as cardiovascular events, gastrointestinal complications, and allergic reactions. Healthcare providers must be vigilant in assessing patient history, comorbidities, and risk factors before prescribing selective COX-2 inhibitors to ensure patient safety and optimal therapeutic outcomes.
Option A, stating that selective COX-2 inhibitors are associated with a low risk of gastric ulceration, is true. Compared to non-selective NSAIDs, COX-2 inhibitors are less likely to cause gastric ulcers and gastrointestinal bleeding.
Option C, claiming that nephrotoxicity is a serious adverse effect of selective COX-2 inhibitors, is incorrect. Nephrotoxicity is not a common side effect associated with these drugs. However, renal function should be monitored in patients taking COX-2 inhibitors as a precaution.
Option D states that Celecoxib should not be given to patients with sulfonamide allergy. This statement is true because Celecoxib has a sulfonamide moiety in its structure, which may cross-react with sulfonamide antibiotics and trigger an allergic reaction in susceptible individuals.
In an educational context, understanding the pharmacological properties and potential adverse effects of selective COX-2 inhibitors is crucial for healthcare professionals in making informed decisions about their use in clinical practice. It is essential to weigh the benefits of these drugs in managing pain and inflammation against their potential risks, such as cardiovascular events, gastrointestinal complications, and allergic reactions. Healthcare providers must be vigilant in assessing patient history, comorbidities, and risk factors before prescribing selective COX-2 inhibitors to ensure patient safety and optimal therapeutic outcomes.